PREVENTION OR TREATMENT OF HEPATIC STEATOSIS

Number of patents in Portfolio can not be more than 2000

United States of America Patent

APP PUB NO 20250025517A1
SERIAL NO

18713999

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

This disclosure is concerned with Anaerobutyricum soehngenii or relative thereof for use in preventing and/or treating hepatic steatosis, particularly nonalcoholic fatty liver disease (NAFLD) and/or nonalcoholic steatohepatitis (NASH), wherein the use is for increasing bile acid plasma level for reducing liver inflammation and/or for reducing hepatic necroinflammatory activity score. The Anaerobutyricum soehngenii or relative thereof may be combined with at least one Bifidobacterium species, preferably Bifidobacterium animalis subspecies lactis or relative thereof and/or Bifidobacterium breve or relative thereof. In addition or alternatively, the Anaerobutyricum soehngenii or relative thereof may be combined with at least one Akkermansia species, preferably Akkermansia muciniphila or relative thereof. In addition or alternatively, the Anaerobutyricum soehngenii or relative thereof may be combined with at least one Lactobacillus species, preferably Lactobacillus acidophilus or relative thereof, Lactobacillus casei or relative thereof and/or Lactobacillus reuteri or relative thereof.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
CAELUS PHARMACEUTICALS B V3474 KG ZEGVELD

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
De, Vos Willem Meindert Amsterdam, NL 38 193
Holleboom, AG Amsterdam, NL 1 0
Nieuwdorp, Max Amsterdam, NL 7 62

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation